SEOUL - South Korea's Yuhan Corp. and San Diego-based clinical stage biopharma Sorrento Therapeutics Inc. have agreed to set up a new joint venture, ImmuneOncia Therapeutics LLC., to develop and commercialize a number of the US firm’s immune checkpoint antibodies against undisclosed targets for both hematological malignancies and solid tumors.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?